MedTrace Logo

Investigation of Genetic Risk of Atrial Fibrillation

NCT00412438 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2006-12-18

No results posted yet for this study

Summary

The atrial fibrillation (AF) is the most common cardiac rhythm disturbance that is responsible for substantial morbidity and mortality independent of associated heart disease or other risk factors. Even in the absence of preexisting cardiovascular disease, AF remains significantly associated with excess mortality rates. The current unsatisfactory treatment for AF comes from lack of understanding of the pathophysiology of AF. The purpose of this study is to identify gene polymorphisms that confer susceptibility to atrial fibrillation. Patients with AF（N=500） and healthy volunteer（N=1000） without AF are enrolled in this study. Patients with coronary artery disease, severe valvular heart disease, cardiomyopathy or heart failure were excluded from the study.

Conditions

Sponsors & Collaborators

  • Nagoya University

    lead OTHER

Principal Investigators

  • Kenji Yasui, MD, Phd · Department of Bio-information Analysis, Research Institute of Enviromental Medicine, Nagoya University

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00412438 on ClinicalTrials.gov